Portal de Periódicos da CAPES

Perioperative Single Dose Instillation of Epirubicin or Interferon-α After Transurethral Resection for The Prophylaxis of Primary Superficial Bladder Cancer Recurrence: A Prospective Randomized Multicenter Study—Finnbladder III Long-Term Results

2002; Lippincott Williams & Wilkins; Volume: 168; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)64556-9

1527-3792

Pertti Rajala, Eero Kaasinen, Mika Raitanen, Tapani Liukkonen, Erkki Rintala,

Esophageal Cancer Research and Treatment

No AccessJournal of UrologyCLINICAL UROLOGY: ORIGINAL ARTICLES1 Sep 2002Perioperative Single Dose Instillation of Epirubicin or Interferon-α After Transurethral Resection for The Prophylaxis of Primary Superficial Bladder Cancer Recurrence: A Prospective Randomized Multicenter Study—Finnbladder III Long-Term Results Pertti Rajala, Eero Kaasinen, Mika Raitanen, Tapani Liukkonen, Erkki Rintala, and the FINNBLADDER GROUP *† Pertti RajalaPertti Rajala , Eero KaasinenEero Kaasinen , Mika RaitanenMika Raitanen , Tapani LiukkonenTapani Liukkonen , Erkki RintalaErkki Rintala , and the FINNBLADDER GROUP *† View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)64556-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the long-term efficacy of a single dose of interferon or epirubicin administered immediately after transurethral resection compared with transurethral resection alone for primary superficial bladder cancer recurrence. Material and Methods: A total of 200 patients with primary superficial stages Ta to T1, grades 1 to 3 bladder cancer were randomized into 3 treatment groups, including transurethral resection alone, transurethral resection plus 50 milliunits interferon-α2b and transurethral resection plus 100 mg. epirubicin. The primary end point was time to first recurrence. Results: At a median followup of 72 months we observed a sustained effect of a single epirubicin instillation compared with other treatments. To date only 46% of the patients in group 3 have experienced recurrence in contrast to 73% and 68% in groups 1 and 2, respectively (p = 0.002). At 72 months the Kaplan-Meier disease-free estimates were 24%, 31% and 51% in groups 1 to 3, respectively (p = 0.002). The Cox multivariate model revealed a more than 2-fold relative risk of recurrence in group 1 versus group 3 (p <0.001). Other significant variables predicting recurrence were grade and the number of tumors. Conclusions: A single perioperative instillation of 100 mg. epirubicin causes a significant and sustained decrease in primary superficial bladder cancer recurrence, whereas a single dose of 50 milliunits interferon-α2b is ineffective for prophylaxis. References 1 : Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol1982; 127: 250. Link, Google Scholar 2 : The biology treatment of superficial bladder cancer. J Clin Oncol1984; 2: 505. Crossref, Medline, Google Scholar 3 : Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer1980; 46: 1158. Crossref, Medline, Google Scholar 4 : Single dose intravesical thiotepa as an adjuvant to cystodiathermy in the treatment of transitional cell bladder carcinoma. Br J Urol1976; 48: 55. Crossref, Medline, Google Scholar 5 : A controlled trial of single dose intravesical adriamycin in superficial bladder tumours. Br J Urol1981; 53: 585. Crossref, Medline, Google Scholar 6 : Influence of thiotepa doxorubicin instillation at time of transurethral surgical treatment of bladder cancer on tumor recurrence: a prospective, randomized, double-blind, controlled trial. J Urol1983; 129: 505. Link, Google Scholar 7 : Single-dose intravesical epodyl after TUR of Ta TCC bladder carcinoma. World J Urol1983; 1: 89. Crossref, Google Scholar 8 : A prospective European Organization for Research Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol1993; 149: 749. Link, Google Scholar 9 : Single-dose versus multiple instillations of epirubicin as prophylaxis for recurrence after transurethral resection of pTa pT1 transitional-cell bladder tumours: a prospective, randomized controlled study. Br J Urol1997; 79: 731. Crossref, Medline, Google Scholar 10 : The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol1996; 155: 1233. Link, Google Scholar 11 : Transurethral resection with perioperative instillation on interferon- or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study—Finnbladder III. J Urol1999; 161: 1133. Link, Google Scholar 12 : Cytostatic effect of different strains of bacillus Calmette-Guerin on human bladder cancer cells in vitro alone in combination with mitomycin C interferon alpha. Urol Res1992; 20: 215. Crossref, Medline, Google Scholar 13 : Histological typing of urinary bladder tumours. International Histological Classification of Tumours. Geneva: World Health Organization1973. No. 10. Google Scholar 14 : Bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 TIS). J Urol1999; 162: 1697. Link, Google Scholar 15 : The significance of perioperative mitomycin C instillation in frequently recurrent superficial bladder carcinoma. J Urol2000; 163: 149. Google Scholar 16 : Recurrence of superficial bladder carcinoma after intravesical instillation of mitomycin-C. Comparison of exposure times. Br J Urol1989; 63: 176. Crossref, Medline, Google Scholar 17 : Intravesical chemotherapy with epirubicin: a dose response study. J Urol1999; 161: 1490. Link, Google Scholar 18 : A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Br J Urol1995; 76: 697. Crossref, Medline, Google Scholar From the Divisions of Urology, Turku University Hospital, Turku, Hyvinkää Hospital, Hyvinkää, Seinäjoki Central Hospital, Seinäjoki, Mikkeli Central Hospital, Mikkeli and Department of Urology, Helsinki University Hospital, Helsinki, Finland© 2002 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited by Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Katayama S, Grossmann N, Mostafai H, Pradere B, Quhal F, Schuettfort V, Roshandel M, Karakiewicz P, Teoh J, Shariat S and Fajkovic H (2021) Impact of enhanced optical techniques at time of transurethral resection of bladder tumour, with or without single immediate intravesical chemotherapy, on recurrence rate of non‐muscle‐invasive bladder cancer: a systematic review and network meta‐analysis of randomized trialsBJU International, 10.1111/bju.15383, VOL. 128, NO. 3, (280-289), Online publication date: 1-Sep-2021. Sharma P and Spiess P (2021) Novel Adjuvant Therapies for Upper Tract Urothelial Carcinoma After Endoscopic Management Bladder Cancer, 10.1007/978-3-030-70646-3_37, (429-438), . Matzner P, Sandbank E, Neeman E, Zmora O, Gottumukkala V and Ben-Eliyahu S (2020) Harnessing cancer immunotherapy during the unexploited immediate perioperative periodNature Reviews Clinical Oncology, 10.1038/s41571-019-0319-9, VOL. 17, NO. 5, (313-326), Online publication date: 1-May-2020. Elsawy A, El-Assmy A, Bazeed M and Ali-El-Dein B (2019) The value of immediate postoperative intravesical epirubicin instillation as an adjunct to standard adjuvant treatment in intermediate and high-risk non–muscle-invasive bladder cancer: A preliminary results of randomized controlled trialUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2018.10.019, VOL. 37, NO. 3, (179.e9-179.e18), Online publication date: 1-Mar-2019. Tanimoto R, Saika T, Ebara S, Kobayashi Y, Nasu R, Yamada D, Takamoto H, Miyaji Y, Nasu Y, Tsushima T and Kumon H (2018) Prospective randomized controlled trial of postoperative early intravesical chemotherapy with pirarubicin (THP) for solitary non-muscle invasive bladder cancer comparing single and two-time instillationWorld Journal of Urology, 10.1007/s00345-018-2196-8, VOL. 36, NO. 6, (889-895), Online publication date: 1-Jun-2018. Crijnen J and De Reijke T (2018) Emerging intravesical drugs for the treatment of non muscle-invasive bladder cancerExpert Opinion on Emerging Drugs, 10.1080/14728214.2018.1474201, VOL. 23, NO. 2, (135-147), Online publication date: 3-Apr-2018. Chou R, Selph S, Buckley D, Fu R, Griffin J, Grusing S and Gore J (2016) Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-AnalysisJournal of Urology, VOL. 197, NO. 5, (1189-1199), Online publication date: 1-May-2017. Kang M, Jeong C, Kwak C, Kim H and Ku J (2016) Single, immediate postoperative instillation of chemotherapy in non-muscle invasive bladder cancer: a systematic review and network meta-analysis of randomized clinical trials using different drugsOncotarget, 10.18632/oncotarget.9991, VOL. 7, NO. 29, (45479-45488), Online publication date: 19-Jul-2016. Sylvester R, Oosterlinck W, Holmang S, Sydes M, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, Ali-El-Dein B, Tatar C, Inman B, N'Dow J, Oddens J and Babjuk M (2016) Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma of the Bladder: Which Patients Benefit from the Instillation?European Urology, 10.1016/j.eururo.2015.05.050, VOL. 69, NO. 2, (231-244), Online publication date: 1-Feb-2016. Neuzillet Y and van Rhijn B (2015) Low-grade Ta urothelial carcinoma of the bladder Advances in Bladder Cancer Management, 10.2217/fmeb2013.13.3, (104-119), Online publication date: 1-Oct-2015. Järvinen R, Marttila T, Kaasinen E, Rintala E, Aaltomaa S, Kallio J, Liukkonen T, Puolakka V, Seppänen M, Tuhkanen K, Vaarala M, Viitanen J and Boström P (2015) Long-term Outcome of Patients with Frequently Recurrent Non–muscle-invasive Bladder Carcinoma Treated with One Perioperative Plus Four Weekly Instillations of Mitomycin C Followed by Monthly Bacillus Calmette-Guérin (BCG) or Alternating BCG and Interferon-α2b Instillations: Prospective Randomised FinnBladder-4 StudyEuropean Urology, 10.1016/j.eururo.2015.02.022, VOL. 68, NO. 4, (611-617), Online publication date: 1-Oct-2015. Türkeri L, Wientjes M and Au J (2015) Intravesical chemotherapy Bladder cancer, 10.1002/9781118674826.ch6, (64-75) Patel S, Cohen A, Weiner A and Steinberg G (2015) Intravesical therapy for bladder cancerExpert Opinion on Pharmacotherapy, 10.1517/14656566.2015.1024656, VOL. 16, NO. 6, (889-901), Online publication date: 13-Apr-2015. Kato T, Nomura K, Kondo F, Wakisaka M and Komiya A (2015) Analysis of Japanese Patients Treated with or without Long-Term Epirubicin Plus Ara-C Intravesical Instillation Therapy for Low-Grade Superficial Bladder CancerThe Scientific World Journal, 10.1155/2015/325305, VOL. 2015, (1-5), . Downs T, Lee D and Scherr D (2015) Management of BCG Recurrent Bladder Cancer Management of Bladder Cancer, 10.1007/978-1-4939-1881-2_20, (245-263), . Elmamoun M, Christmas T and Woodhouse C (2013) Destruction of the bladder by single dose Mitomycin C for low-stage transitional cell carcinoma (TCC) - avoidance, recognition, management and consentBJU International, 10.1111/bju.12340, VOL. 113, NO. 5b, (E34-E38), Online publication date: 1-May-2014. Lamm D, Brausi M, O'Donnell M and Witjes J (2014) Interferon alfa in the treatment paradigm for non–muscle-invasive bladder cancerUrologic Oncology: Seminars and Original Investigations, 10.1016/j.urolonc.2013.02.010, VOL. 32, NO. 1, (35.e21-35.e30), Online publication date: 1-Jan-2014. van Lingen A, Arends T and Witjes J (2014) Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancerExpert Review of Anticancer Therapy, 10.1586/14737140.2013.852474, VOL. 13, NO. 11, (1257-1268), Online publication date: 1-Nov-2013. Perlis N, Zlotta A, Beyene J, Finelli A, Fleshner N and Kulkarni G (2013) Immediate Post–Transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non–Muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence ReviewEuropean Urology, 10.1016/j.eururo.2013.06.009, VOL. 64, NO. 3, (421-430), Online publication date: 1-Sep-2013. Shin Y, Kim J, Ko O, Doo A, Kim M, Jeong Y and Kim H (2012) The Direct Anti-Cancer Effect of a Single Instillation of Epirubicin after Transurethral Resection of Bladder Tumor for Non-Muscle-Invasive Bladder CancerKorean Journal of Urology, 10.4111/kju.2012.53.2.78, VOL. 53, NO. 2, (78), . Chamie K, Saigal C, Lai J, Hanley J, Setodji C, Konety B and Litwin M (2011) Compliance with guidelines for patients with bladder cancerCancer, 10.1002/cncr.26198, VOL. 117, NO. 23, (5392-5401), Online publication date: 1-Dec-2011. Oosterlinck W, Sylvester R, Babjuk M, Kaasinen E, Böhle A, Palou-Redorta J and Rouprêt M (2011) Should All Patients Receive an Immediate Chemotherapeutic Drug Instillation After Resection of Papillary Bladder Tumors?European Urology, 10.1016/j.eururo.2010.12.002, VOL. 59, NO. 3, (374-376), Online publication date: 1-Mar-2011. Adiyat K, Katkoori D and Soloway M (2011) Intravesical Chemotherapy Bladder Tumors:, 10.1007/978-1-60761-928-4_13, (253-270), . Oosterlinck W (2011) Clinical Management of Low Grade Bladder Tumors Bladder Tumors:, 10.1007/978-1-60761-928-4_11, (217-236), . Williams S, Hoenig D, Ghavamian R and Soloway M (2010) Intravesical therapy for bladder cancerExpert Opinion on Pharmacotherapy, 10.1517/14656561003657145, VOL. 11, NO. 6, (947-958), Online publication date: 1-Apr-2010. Smaldone M, Casella D, Welchons D and Gingrich J (2010) Investigational therapies for non-muscle invasive bladder cancerExpert Opinion on Investigational Drugs, 10.1517/13543780903563372, VOL. 19, NO. 3, (371-383), Online publication date: 1-Mar-2010. Rouprêt M, Guillotreau J, Irani J and Zerbib M (2010) Prise en charge des tumeurs vésicales non-infiltrant le muscle vésical. TaG1 : intérêt de l'IPOP ?Progrès en Urologie, 10.1016/S1166-7087(10)70026-9, VOL. 20, (S46-S49), Online publication date: 1-Mar-2010. (2010) Evidence-based clinical practice guidelines for bladder cancer (Summary - JUA 2009 Edition)International Journal of Urology, 10.1111/j.1442-2042.2010.02486.x, VOL. 17, NO. 2, (102-124), Online publication date: 1-Feb-2010. Wu W, Ke H, Yang Y, Li C, Chou Y and Huang C (2009) Should Patients With Primary Upper Urinary Tract Cancer Receive Prophylactic Intravesical Chemotherapy After Nephroureterectomy?Journal of Urology, VOL. 183, NO. 1, (56-61), Online publication date: 1-Jan-2010. Hussain M, Wood D, Bajorin D, Bochner B, Dreicer R, Lamm D, O'Donnell M, Siefker-Radtke A, Theodorescu D and Dinney C (2009) Bladder Cancer: Narrowing the Gap Between Evidence and PracticeJournal of Clinical Oncology, 10.1200/JCO.2009.23.6901, VOL. 27, NO. 34, (5680-5684), Online publication date: 1-Dec-2009. Tyritzis S, Stravodimos K, Mihalakis A and Constantinides C (2009) Complications associated with primary and secondary perforation of the bladder following immediate instillations of epirubicin after transurethral resection of superficial urothelial tumoursInternational Urology and Nephrology, 10.1007/s11255-009-9536-y, VOL. 41, NO. 4, (865-868), Online publication date: 1-Dec-2009. Maffezzini M, Campodonico F, Puntoni M, Martelli A and Mattioli F (2009) Systemic Absorption and Pharmacokinetics of Single-dose Intravesical Gemcitabine After Transurethral Resection of the Bladder in Non-muscle-invasive Bladder CancerUrology, 10.1016/j.urology.2009.05.094, VOL. 74, NO. 5, (1078-1083), Online publication date: 1-Nov-2009. Böhle A, Leyh H, Frei C, Kühn M, Tschada R, Pottek T, Wagner W, Knispel H, von Pokrzywnitzki W, Zorlu F, Helsberg K, Lübben B, Soldatenkova V, Stoffregen C and Büttner H (2009) Single Postoperative Instillation of Gemcitabine in Patients with Non-muscle-invasive Transitional Cell Carcinoma of the Bladder: A Randomised, Double-blind, Placebo-controlled Phase III Multicentre StudyEuropean Urology, 10.1016/j.eururo.2009.06.010, VOL. 56, NO. 3, (495-503), Online publication date: 1-Sep-2009. Gudjónsson S, Adell L, Merdasa F, Olsson R, Larsson B, Davidsson T, Richthoff J, Hagberg G, Grabe M, Bendahl P, Månsson W and Liedberg F (2009) Should All Patients with Non–Muscle-Invasive Bladder Cancer Receive Early Intravesical Chemotherapy after Transurethral Resection? The Results of a Prospective Randomised Multicentre StudyEuropean Urology, 10.1016/j.eururo.2009.01.006, VOL. 55, NO. 4, (773-780), Online publication date: 1-Apr-2009. Solsona E (2009) Early Single Instillation Chemotherapy Is Very Beneficial and Should Be the Standard Approach in Non–Muscle-Invasive Bladder CancerEuropean Urology Supplements, 10.1016/j.eursup.2009.01.001, VOL. 8, NO. 5, (464-469), Online publication date: 1-Apr-2009. Holmäng S (2009) Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder CancerEuropean Urology Supplements, 10.1016/j.eursup.2008.12.003, VOL. 8, NO. 5, (458-463), Online publication date: 1-Apr-2009. Rao P and Stephen Jones J (2009) Routine perioperative chemotherapy instillation with initial bladder tumor resectionCancer, 10.1002/cncr.24104, VOL. 115, NO. 5, (997-1004), Online publication date: 1-Mar-2009. Cai T, Nesi G, Tinacci G, Zini E, Mondaini N, Boddi V, Mazzoli S and Bartoletti R (2008) Can Early Single Dose Instillation of Epirubicin Improve Bacillus Calmette-Guerin Efficacy in Patients With Nonmuscle Invasive High Risk Bladder Cancer? Results From a Prospective, Randomized, Double-Blind Controlled StudyJournal of Urology, VOL. 180, NO. 1, (110-115), Online publication date: 1-Jul-2008.Berrum-Svennung I, Granfors T, Jahnson S, Boman H and Holmäng S (2007) A Single Instillation of Epirubicin After Transurethral Resection of Bladder Tumors Prevents Only Small RecurrencesJournal of Urology, VOL. 179, NO. 1, (101-106), Online publication date: 1-Jan-2008. Josephson D, Pasin E and Stein J (2014) Superficial bladder cancer: part 2. Management.Expert Review of Anticancer Therapy, 10.1586/14737140.7.4.567, VOL. 7, NO. 4, (567-581), Online publication date: 1-Apr-2007. Doehn C, Huland E, Jäger T, Jocham D, Krege S, Rübben H, Schleucher N, Seeber S and Vanhoefer U (2007) Grundlagen der systemischen Therapie Uroonkologie, 10.1007/978-3-540-33848-2_6, (55-96), . Wilson S (2006) Genitourinary malignanciesUpdate on Cancer Therapeutics, 10.1016/j.uct.2006.08.007, VOL. 1, NO. 4, (443-466), Online publication date: 1-Dec-2006. Liu B, Wang Z, Chen B, Yu J, Zhang P, Ding Q and Zhang Y (2009) Randomized Study of Single Instillation of Epirubicin for Superficial Bladder Carcinoma: Long-Term Clinical OutcomesCancer Investigation, 10.1080/07357900500524405, VOL. 24, NO. 2, (160-163), Online publication date: 1-Jan-2006. Oosterlinck W, Solsona E, Akaza H, Busch C, Goebell P, Malmström P, Özen H and Sved P (2005) Low-grade Ta (noninvasive) urothelial carcinoma of the bladderUrology, 10.1016/j.urology.2005.07.063, VOL. 66, NO. 6, (75-89), Online publication date: 1-Dec-2005. O'Donnell M (2005) Practical Applications of Intravesical Chemotherapy and Immunotherapy in High-risk Patients with Superficial Bladder CancerUrologic Clinics of North America, 10.1016/j.ucl.2005.01.003, VOL. 32, NO. 2, (121-131), Online publication date: 1-May-2005. Doehn C, Kausch I and Jocham D (2005) Immuntherapie urologischer TumorenImmunotherapy of urologic tumorsDer Onkologe, 10.1007/s00761-005-0876-7, VOL. 11, NO. 5, (536-553), Online publication date: 1-May-2005. Sylvester R, Oosterlinck W and van der Meijden A (2018) RE: A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 173, NO. 4, (1433-1433), Online publication date: 1-Apr-2005. Wilson S and Crawford E (2005) Genitourinary malignancies , 10.1016/S0921-4410(04)22022-1, (485-513), . Langbein S, H�cker A, Badawi J, Michel M and Alken P (2004) Die Fr�hinstillation des HarnblasenkarzinomsSingle early postoperative instillation in superficial bladder carcinoma?current statusDer Urologe, Ausgabe A, 10.1007/s00120-004-0720-5, VOL. 43, NO. 12, (1531-1536), Online publication date: 1-Dec-2004. Perabo F and Müller S (2004) Current and new strategies in immunotherapy for superficial bladder cancerUrology, 10.1016/j.urology.2004.04.026, VOL. 64, NO. 3, (409-421), Online publication date: 1-Sep-2004. Oddens J, van der Meijden A and Sylvester R (2004) One Immediate Postoperative Instillation of Chemotherapy in Low Risk Ta, T1 Bladder Cancer Patients. Is it Always Safe?European Urology, 10.1016/j.eururo.2004.05.003, VOL. 46, NO. 3, (336-338), Online publication date: 1-Sep-2004. SYLVESTER R, OOSTERLINCK W and van der MEIJDEN A (2018) A SINGLE IMMEDIATE POSTOPERATIVE INSTILLATION OF CHEMOTHERAPY DECREASES THE RISK OF RECURRENCE IN PATIENTS WITH STAGE Ta T1 BLADDER CANCER: A META-ANALYSIS OF PUBLISHED RESULTS OF RANDOMIZED CLINICAL TRIALSJournal of Urology, VOL. 171, NO. 6 Part 1, (2186-2190), Online publication date: 1-Jun-2004. Patard J, Rodriguez A and Lobel B (2003) The current status of intravesical therapy for superficial bladder cancerCurrent Opinion in Urology, 10.1097/00042307-200309000-00002, VOL. 13, NO. 5, (357-362), Online publication date: 1-Sep-2003. van der Heijden A and Witjes J (2003) Intravesical Chemotherapy: An Update—New Trends and PerspectivesEAU Update Series, 10.1016/S1570-9124(03)00020-5, VOL. 1, NO. 2, (71-79), Online publication date: 1-Jun-2003. Borden, L, Clark P and Hall M (2003) Bladder cancerCurrent Opinion in Oncology, 10.1097/00001622-200305000-00009, VOL. 15, NO. 3, (227-233), Online publication date: 1-May-2003. Volume 168Issue 3September 2002Page: 981-985 Advertisement Copyright & Permissions© 2002 by American Urological Association, Inc.Keywordsadministration, intravesicalbladderbladder neoplasmsinterferon-alphaepirubicinMetricsAuthor Information Pertti Rajala More articles by this author Eero Kaasinen More articles by this author Mika Raitanen More articles by this author Tapani Liukkonen More articles by this author Erkki Rintala More articles by this author the FINNBLADDER GROUP *† Members: M. Ala-Opas and K. Tuhkanen, Kuopio University Hospital, Kuopio; T. Forsell, Kymenlaakso Central Hospital, Kotka; P. Granbacka, Pietarsaari Hospital, Pietarsaari; O. Hynninen, K. Lehtoranta and M. Talja, Päijät-Häme Central Hospital, Lahti; K. Jauhiainen and T. Liukkonen, Mikkeli Central Hospital, Mikkeli, H. Juusela, Jorvi Hospital, Espoo; E. Kaasinen; Hyvinkää Hospital, Hyvinkää; P. Kemppainen, Central Hospital of Kainuu, Kajaani; H. Korhonen; Satakunta Central Hospital, Pori; T. Lahdes-Vasama, S. Rannikko, E. Rintala and M. Ruutu; Helsinki University Hospital, Helsinki; P. Hällström, M. Kontturi and O. Lukkarinen, Oulu University Hospital, Oulu; M. Nurmi and P. Rajala, Turku University Hospital, Turku; J. Ottelin, Kemi Central Hospital, Kemi; P. Pellinen, Etelä-Pohjanmaa Central Hospital, Kokkola; J. Permi and V.-M. Puolakka, Etelä-Saimaa Central Hospital, Lappeenranta; T. L. Tammela, J. Häkkinen and H. Tainio, Tampere University Hospital, Tampere; R. Usenius, Central-Finland Central Hospital, Jyväskylä; and J. Viitanen, Pohjois-Karjala Central Hospital, Joensuu, Finland. More articles by this author Expand All Advertisement PDF downloadLoading ...